WEIGHT
WEEKS
The only registered single agent for Chronic Weight Management that activates both GIP and GLP-1 receptors 1 , 3
SURMOUNT-1 SURMOUNT-4 SURMOUNT-1 & 4
WEIGHT
Superior
-22.5 % body weight reduction vs placebo (– 2.4 %) 1 *
88
WEEKS
Significant
-26.0 % body weight reduction vs placebo (– 9.5 %) 4 ‡
Improved key cardiometabolic § parameters vs placebo 4 , 5 ¶
62.9 %
Achieved ≥20 % body weight reduction vs placebo ( 1.3 %) 1 †
Scan the QR code to learn more about Mounjaro
* Percentage body weight change from baseline to week 72 with Mounjaro 15 mg maintenance dose , p < 0.001 ; -20.1 % difference from placebo , p < 0.001 , adjusted for multiplicity ( mITT population ). 1
† Percentage of participants achieving ≥20 % body weight reduction with Mounjaro 15 mg maintenance dose vs placebo , p < 0.001 , adjusted for multiplicity . 1
‡ Additional secondary endpoint : p < 0.001 for percentage body weight change vs placebo for weeks 0 to 88 , not adjusted for multiplicity . Efficacy estimand , MMRM analysis , data are LS means ( treatment-regimen estimand = -25.3%, p < 0.001 , data are observed mean values ). 4 All primary and secondary endpoints met statistical significance , p < 0.001 . 4
§
Mounjaro is not indicated to improve key cardiometabolic parameters , including waist circumference , blood pressure ( systolic and diastolic ), cholesterol ( total , non-HDL , HDL , and LDL ) and triglycerides . 1 Cardiometabolic parameters were secondary endpoints in SURMOUNT-1 and SURMOUNT-4 . 4 , 5
¶
SURMOUNT-1 : Waist circumference : Mounjaro 5 mg , 10 mg and 15 mg vs placebo , p < 0.001 ( 5 mg not adjusted for multiplicity ). 1 Triglycerides , HDL and non-HDL cholesterols , and systolic blood pressure : pooled Mounjaro groups vs placebo , p < 0.001 ; diastolic blood pressure and total and LDL cholesterols , p-values not reported . 5 Key secondary endpoints were adjusted for multiplicity . 5 SURMOUNT-4 : systolic and diastolic blood pressure , triglycerides and LDL cholesterol , p < 0.001 , Mounjaro MTD vs placebo , not adjusted for multiplicity ; HDL cholesterol , p = 0.014 , Mounjaro MTD vs placebo , not adjusted for multiplicity . 4
SURMOUNT-1 was powered to show superiority of Mounjaro ( 10 mg , 15 mg , or both ) to placebo with respect to the coprimary endpoints from baseline to week 72 . 5
Studied in adults with obesity ( BMI of ≥30 kg / m 2 ) or with overweight ( BMI of ≥27 kg / m 2 to < 30 kg / m 2 ) with at least 1 weight-related complication , excluding type 2 diabetes . 1 All participants in SURMOUNT-1 and SURMOUNT-4 received lifestyle intervention , including a reduced-calorie diet and increased physical activity . 1 , 4 , 5
SURMOUNT-4 was a Phase 3 clinical trial with a 36-week lead-in period , in which all participants received Mounjaro maximum tolerated dose ( 10 mg or 15 mg ), and a 52-week double-blind period , in which participants were randomised to MTD or placebo . 4
Safety profile : Common adverse events with Mounjaro in SURMOUNT-1 and SURMOUNT-4 included nausea , diarrhoea , constipation and vomiting . 4 , 5 These adverse events were mostly mild or moderate in severity , occurred more often during dose escalation , and decreased over time . 1 , 4 , 5
PBS Information : Mounjaro ® ( tirzepatide ) is not listed on the PBS .
Please refer to the full Product Information before prescribing . Product Information can be accessed at www . lilly . com . au / en / products , or by scanning the QR code , or on request by calling 1800 454 559 .
This medicinal product is subject to additional monitoring in Australia due to approval of an extension of indications . This will allow quick identification of new safety information . Healthcare professionals are asked to report any suspected adverse events at www . tga . gov . au / reporting-problems .
© Eli Lilly Australia Pty Limited . Mounjaro ® is a registered trademark of Eli Lilly and Company . Eli Lilly Australia Pty Limited . ABN 39 000 233 992 . Level 9 , 60 Margaret St , Sydney NSW 2000 . Telephone : 1800 454 559 . Date of preparation : October 2024 . PP-TR-AU-0430 . 2007101 .